Display options
Cite
Aaby P, Martins CL, Garly ML, et al. The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy. BMJ Open. 2012;2(4)doi: 10.1136/bmjopen-2011-000761.
Aaby, P., Martins, C. L., Garly, M. L., Rodrigues, A., Benn, C. S., & Whittle, H. (2012). The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy. BMJ open, 2(4), . https://doi.org/10.1136/bmjopen-2011-000761
Aaby, Peter, et al. "The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy." BMJ open vol. 2,4 (2012). doi: https://doi.org/10.1136/bmjopen-2011-000761
Aaby P, Martins CL, Garly ML, Rodrigues A, Benn CS, Whittle H. The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy. BMJ Open. 2012 Jul 19;2(4). doi: 10.1136/bmjopen-2011-000761. Print 2012. PMID: 22815465; PMCID: PMC3401826.
Copy Download .nbib Format: NLM
Share it on

BMJ Open. 2012 Jul 19;2(4). doi: 10.1136/bmjopen-2011-000761. Print 2012.

The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy.

BMJ open

Peter Aaby, Cesário L Martins, May-Lill Garly, Amabelia Rodrigues, Christine S Benn, Hilton Whittle

Affiliations

  1. Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.

PMID: 22815465 PMCID: PMC3401826 DOI: 10.1136/bmjopen-2011-000761

Abstract

OBJECTIVE: The current policy of measles vaccination at 9 months of age was decided in the mid-1970s. The policy was not tested for impact on child survival but was based on studies of seroconversion after measles vaccination at different ages. The authors examined the empirical evidence for the six underlying assumptions.

DESIGN: Secondary analysis.

DATA SOURCES AND METHODS: These assumptions have not been research issues. Hence, the authors examined case reports to assess the empirical evidence for the original assumptions. The authors used existing reviews, and in December 2011, the authors made a PubMed search for relevant papers. The title and abstract of papers in English, French, Portuguese, Spanish, German and Scandinavian languages were assessed to ascertain whether the paper was potentially relevant. Based on cumulative measles incidence figures, the authors calculated how many measles cases had been prevented assuming everybody was vaccinated at a specific age, how many 'vaccine failures' would occur after the age of vaccination and how many cases would occur before the specific age of vaccination. In the combined analyses of several studies, the authors used the Mantel-Haenszel weighted RR stratifying for study or age groups to estimate common trends.

SETTING AND PARTICIPANTS: African community studies of measles infection.

PRIMARY AND SECONDARY OUTCOMES: Consistency between assumptions and empirical evidence and the predicted effect on mortality.

RESULTS: In retrospect, the major assumptions were based on false premises. First, in the single study examining this point, seronegative vaccinated children had considerable protection against measles infection. Second, in 18 community studies, vaccinated measles cases ('vaccine failures') had threefold lower case death than unvaccinated cases. Third, in 24 community studies, infants had twofold higher case death than older measles cases. Fourth, the only study examining the assumption that 'vaccine failures' lead to lack of confidence found the opposite because vaccinated children had milder measles infection. Fifth, a one-dose policy was recommended. However, the two randomised trials of early two-dose measles vaccination compared with one-dose vaccination found significantly reduced mortality until 3 years of age. Thus, current evidence suggests that the optimal age for a single dose of measles vaccine should have been 6 or 7 months resulting in fewer severe unvaccinated cases among infants but more mild 'vaccine failures' among older children. Furthermore, the two-dose trials indicate that measles vaccine reduces mortality from other causes than measles infection.

CONCLUSIONS: Many lives may have been lost by not determining the optimal age of measles vaccination. Since seroconversion continues to be the basis for policy, the current recommendation is to increase the age of measles vaccination to 12 months in countries with limited measles transmission. This policy may lead to an increase in child mortality.

References

  1. PLoS Med. 2007 Jan;4(1):e16 - PubMed
  2. West Afr Med J. 1964 Dec;13:251-7 - PubMed
  3. Trop Med Int Health. 1998 Sep;3(9):751-6 - PubMed
  4. J Trop Pediatr. 1999 Apr;45(2):98-104 - PubMed
  5. Lancet. 2003 Jun 28;361(9376):2183-8 - PubMed
  6. Am J Epidemiol. 1997 Oct 15;146(8):646-54 - PubMed
  7. J Infect Dis. 1990 Nov;162(5):1043-8 - PubMed
  8. Int J Epidemiol. 2005 Feb;34(1):138-48 - PubMed
  9. Bull Pan Am Health Organ. 1982;16(3):272-85 - PubMed
  10. Int J Epidemiol. 1999 Apr;28(2):347-52 - PubMed
  11. Lancet. 1983 Dec 24-31;2(8365-66):1470-2 - PubMed
  12. Cent Afr J Med. 1995 Nov;41(11):336-9 - PubMed
  13. Arch Dis Child. 2010 Sep;95(9):662-7 - PubMed
  14. J Trop Pediatr. 2006 Oct;52(5):329-34 - PubMed
  15. JAMA. 1996 Jan 17;275(3):224-9 - PubMed
  16. Clin Infect Dis. 2006 Feb 1;42(3):322-8 - PubMed
  17. Eur J Immunol. 1998 Dec;28(12):4138-48 - PubMed
  18. Trans R Soc Trop Med Hyg. 1982;76(4):529-30 - PubMed
  19. BMJ. 1995 Aug 19;311(7003):481-5 - PubMed
  20. Rev Infect Dis. 1988 Mar-Apr;10(2):478-91 - PubMed
  21. Trans R Soc Trop Med Hyg. 1980;74(3):381-2 - PubMed
  22. Int J Epidemiol. 2003 Feb;32(1):106-16 - PubMed
  23. Bull World Health Organ. 1993;71(3-4):421-8 - PubMed
  24. Epidemiol Infect. 1994 Apr;112(2):413-20 - PubMed
  25. East Afr Med J. 2001 Mar;78(3):135-8 - PubMed
  26. Afr J Med Sci. 1971 Apr;2(2):151-8 - PubMed
  27. Indian J Community Med. 2009 Apr;34(2):117-21 - PubMed
  28. East Afr Med J. 1992 Aug;69(8):419-23 - PubMed
  29. Lancet. 1981 Apr 4;1(8223):764-7 - PubMed
  30. BMJ. 2010 Nov 30;341:c6495 - PubMed
  31. Trop Med Int Health. 2005 Oct;10(10):956-60 - PubMed
  32. J Infect. 1984 Jan;8(1):13-21 - PubMed
  33. Scand J Infect Dis. 1997;29(2):187-90 - PubMed
  34. J Natl Med Assoc. 1973 Sep;65(5):378-85 - PubMed
  35. Lancet. 2010 Nov 20;376(9754):1719-20 - PubMed
  36. Vaccine. 2001 Dec 12;20(5-6):949-53 - PubMed
  37. Acta Trop. 2003 Jan;85(1):1-17 - PubMed
  38. Pediatr Infect Dis J. 2007 Mar;26(3):247-52 - PubMed
  39. Pediatrics. 1990 Feb;85(2):188-94 - PubMed
  40. Trans R Soc Trop Med Hyg. 1981;75(1):128-9 - PubMed
  41. J Infect Dis. 1986 Nov;154(5):858-63 - PubMed
  42. Epidemiol Infect. 2002 Oct;129(2):361-9 - PubMed
  43. Int J Epidemiol. 1994 Feb;23(1):185-93 - PubMed
  44. Int J Epidemiol. 2009 Feb;38(1):192-205 - PubMed
  45. J Infect Dis. 2004 May 1;189 Suppl 1:S227-35 - PubMed
  46. Indian Pediatr. 1998 Aug;35(8):723-5 - PubMed
  47. Am J Epidemiol. 1995 Sep 15;142(6):643-52 - PubMed
  48. BMJ. 2010 May 18;340:c1626 - PubMed
  49. Wkly Epidemiol Rec. 2009 Aug 28;84(35):349-60 - PubMed
  50. Int J Epidemiol. 1991 Jun;20(2):474-9 - PubMed
  51. Pediatr Infect Dis J. 1989 Apr;8(4):197-200 - PubMed
  52. Br Med J (Clin Res Ed). 1988 Apr 30;296(6631):1225-8 - PubMed
  53. Am J Epidemiol. 1984 Jul;120(1):49-63 - PubMed
  54. East Afr Med J. 1995 Mar;72(3):155-61 - PubMed
  55. Trans R Soc Trop Med Hyg. 1976;70(3):206-12 - PubMed
  56. Vaccine. 2006 Apr 5;24(15):2764-71 - PubMed
  57. Pediatr Infect Dis J. 2003 Sep;22(9):798-805 - PubMed
  58. BMJ. 1993 Nov 20;307(6915):1308-11 - PubMed
  59. Pediatr Infect Dis J. 1995 Mar;14(3):203-9 - PubMed
  60. BMJ. 2008 Jul 24;337:a661 - PubMed
  61. Ann Trop Paediatr. 1995 Jun;15(2):167-72 - PubMed
  62. Trans R Soc Trop Med Hyg. 1993 Nov-Dec;87(6):697-701 - PubMed
  63. BMC Int Health Hum Rights. 2010 Mar 19;10:5 - PubMed
  64. Wkly Epidemiol Rec. 2007 Jan 12;82(1-2):1-16 - PubMed
  65. Epidemiol Infect. 1995 Oct;115(2):309-14 - PubMed
  66. Scand J Infect Dis. 1993;25(6):763-9 - PubMed
  67. Lancet. 1981 Aug 1;2(8240):236-7 - PubMed
  68. Lancet. 2005 Sep 3-9;366(9488):832-9 - PubMed
  69. Rev Infect Dis. 1988 Mar-Apr;10(2):474-7 - PubMed
  70. Int J Epidemiol. 2010 Apr;39 Suppl 1:i48-55 - PubMed
  71. Pediatr Infect Dis J. 1996 Jan;15(1):39-44 - PubMed
  72. Rev Infect Dis. 1983 May-Jun;5(3):554-7 - PubMed
  73. J Trop Pediatr. 1984 Jun;30(3):164-8 - PubMed
  74. Am J Epidemiol. 1997 Jan 1;145(1):51-7 - PubMed
  75. J Infect Dis. 2006 Jun 1;193(11):1528-35 - PubMed
  76. Trans R Soc Trop Med Hyg. 1975;69(1):31-5 - PubMed
  77. Med Trop (Mars). 1979 Jan-Feb;39(1):71-9 - PubMed
  78. Am J Epidemiol. 1993 Nov 1;138(9):746-55 - PubMed
  79. Pediatr Infect Dis J. 1998 Nov;17(11):1034-9 - PubMed
  80. Int J Epidemiol. 1981 Sep;10(3):263-9 - PubMed
  81. Lancet. 1983 Apr 30;1(8331):972-5 - PubMed
  82. Bull World Health Organ. 1977;55(1):21-31 - PubMed
  83. Int J Epidemiol. 1996 Jun;25(3):665-73 - PubMed
  84. P N G Med J. 2000 Mar-Jun;43(1-2):91-7 - PubMed
  85. Bull World Health Organ. 2004 Feb;82(2):134-8 - PubMed
  86. BMJ. 2000 Dec 9;321(7274):1435-8 - PubMed
  87. East Afr Med J. 1977 Jul;54(7):364-72 - PubMed
  88. Wkly Epidemiol Rec. 1993 May 14;68(20):142-5 - PubMed
  89. Nat Rev Immunol. 2002 Jun;2(6):417-26 - PubMed

Publication Types

Grant support